Developer docs
API playgroundTry for free, no card

Search company profiles

Virobay

Full company profile

uuid000ofbg

Namestring
Virobay
Legal namestring
Virobay Inc.
Websiteurl
virobayinc.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Virobay Inc. is a privately held, virtual biotechnology company founded in 2006 in Menlo Park, California, developing small-molecule cathepsin protease inhibitors for autoimmune diseases, neuropathic pain, liver fibrosis, atherosclerosis, and cancer. The company's pipeline comprises six drug candidates — VBY-036, VBY-129, VBY-285, and VBY-891 (cathepsin S inhibitors for pain, autoimmunity, Alzheimer's, and dermatology), VBY-376 (cathepsin B inhibitor for liver fibrosis), and VBY-825 (pan-cathepsin inhibitor for oncology) — characterized as potent, orally bioavailable, reversible inhibitors with picomolar-to-nanomolar potency and selectivity profiles designed to overcome historical cathepsin inhibitor design challenges. Virobay operates an asset-light model with a 1–10 person in-house team that coordinates globally distributed contract research and manufacturing organizations, with senior leaders drawn from Roche, Celera Genomics, Sugen, Merck, and other tier-one organizations.

The company is backed by venture investors including Alta Partners, Sutter Hill Ventures, TPG Growth, Perceptive Advisors, and strategic investor AbbVie, with cumulative disclosed funding on the order of $23M–$24M across a 2006 seed, 2010 Series B ($10M), and 2014 Series B extension ($8M). Virobay is pre-revenue and monetizes exclusively through pharmaceutical partnerships: the model is to advance compounds through preclinical and Phase 1 development, then license or co-develop with larger pharma for late-stage trials and commercialization. The flagship deal is a multi-million dollar January 2012 collaboration with LEO Pharma A/S for VBY-891 in oral psoriasis treatment, which advanced to Phase 1 in 2013 alongside Virobay's wholly owned VBY-036 in neuropathic pain. With no commercialized products, the company has not disclosed revenue, and recent verifiable company-driven updates stop at 2013.

Short descriptiontext

Virobay is a privately held, virtual biotechnology company developing small-molecule cathepsin protease inhibitors for autoimmune diseases, neuropathic pain, liver fibrosis, and cancer, advancing six drug candidates through preclinical and Phase 1 stages and partnering with pharmaceutical companies for late-stage development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule drug discovery, cathepsin protease inhibitors, autoimmune disease therapeutics, neuropathic pain treatments, oncology drug development
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Small Molecule Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Partnership/Licensing Revenue
TypeLicensing Royalties
Description

Virobay develops drug candidates through clinical development and out-licenses or partners with pharmaceutical companies for later-stage development and commercialization. Revenue would come from upfront payments, milestone payments, and royalties from partnership agreements such as the LEO Pharma collaboration.

virobayinc.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Virobay discovers and develops orally bioavailable small-molecule cysteine protease (cathepsin) inhibitors as drug candidates for autoimmune diseases, neuropathic pain, liver fibrosis, atherosclerosis, and cancer. The company advances these candidates through preclinical and early clinical stages using a virtual operating model and then partners or licenses them to pharmaceutical companies for late-stage development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Cathepsin S inhibitor reduced atherosclerotic plaques by 68% in female mice and 36% in male mice after 8 weeks of dosing
+3 more records
Product overview1 text field

Virobay is a drug discovery and development company specializing in protease inhibitor design for the treatment of autoimmune diseases, neuropathic pain, liver diseases, and cancer. The company's product portfolio consists of six distinct drug candidates targeting cathepsin proteases: VBY-036 (cathepsin S inhibitor for neuropathic pain/Alzheimer's), VBY-129 (cathepsin S inhibitor for autoimmune diseases), VBY-285 (next-gen cathepsin S inhibitor), VBY-891 (cathepsin S inhibitor for dermatology partnered with LEO Pharma), VBY-376 (cathepsin B inhibitor for liver fibrosis), and VBY-825 (pan-cathepsin inhibitor for oncology). Compounds include both highly selective inhibitors targeting individual cathepsins and broadly acting pan-cathepsin inhibitors. The company operates a virtual model combining in-house expertise with contract research and manufacturing facilities worldwide.

Product and service6 records
1VBY-036
CategoryDrug Candidate
Description

VBY-036 is a next-generation, orally bioavailable, potent, competitive and reversible cathepsin S inhibitor with picomolar enzyme potency and nanomolar cellular potency. It is highly selective against cathepsins B, F, L, and K and is suitable for once-daily dosing in humans. It targets neuropathic pain and Alzheimer's Disease.

2VBY-129
CategoryDrug Candidate
Description

VBY-129 is a potent, competitive, reversible inhibitor of purified cathepsin S with high selectivity against other human cathepsins. It demonstrated sustained inhibition of cathepsin S after once-daily oral dosing in a Phase 1 clinical trial and targets autoimmune diseases.

3VBY-285
CategoryDrug Candidate
Description

VBY-285 is a next-generation cathepsin S inhibitor, structurally distinct from VBY-129, VBY-891, and VBY-036. It is a potent, competitive, reversible inhibitor with picomolar potency against cathepsin S, selectively inhibits cathepsin S over B, F, L, and K, and is orally bioavailable in preclinical studies. It has shown efficacy in autoimmunity and neuropathic pain models.

4VBY-891
CategoryDrug Candidate
Description

VBY-891 is a next-generation cathepsin S inhibitor, structurally distinct from other cathepsin S inhibitors, with picomolar enzyme potency and nanomolar cellular potency, high selectivity against cathepsins L, B, F, and K, and oral bioavailability suitable for once-daily dosing. It is being developed in partnership with LEO Pharma as an oral treatment for psoriasis (dermatology).

5VBY-376
CategoryDrug Candidate
Description

VBY-376 is a potent, competitive, reversible inhibitor of cathepsin B with nanomolar potency, selectively inhibiting cathepsin B over F, L, V, and S. A human Phase 1 study showed exposure levels overlapping those required for antifibrotic efficacy. It targets liver fibrosis.

6VBY-825
CategoryDrug Candidate
Description

VBY-825 is a potent, competitive, reversible pan-cathepsin protease inhibitor with picomolar or low nanomolar potency across all cathepsins implicated in cancer. It demonstrated efficacy in spontaneous tumor models with effects on primary tumor burden and tumor vasculature. It targets bone cancer/oncology.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

Virobay Inc. and LEO Pharma initiated a collaboration in January 2012 to develop an oral treatment for psoriasis using VBY-891, a cathepsin S inhibitor. This multi-million dollar collaboration represents Virobay's primary partnership for dermatology indications. Virobay retains rights to compounds while LEO Pharma provides development and commercialization expertise for the psoriasis indication.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Belgian biotech with a small-molecule pipeline in inflammation and immunology; comparable in therapeutic focus (autoimmune/inflammation) and chemistry modality (oral small molecules) though at a much larger scale.

2ChemoCentryx (Amgen)
TypeBroad incumbent
Description

Small-molecule immunology company acquired by Amgen, focused on complement and chemokine pathways for autoimmune diseases; comparable as a small-molecule immunology developer targeting similar autoimmune indications.

TypeEmerging player
Description

Clinical-stage biotech developing novel small-molecule therapies for immune-mediated diseases; comparable as a small-cap small-molecule immunology developer pursuing partnerships for commercialization.

TypeDirect peer
Description

Germany-based company developing small-molecule cathepsin D inhibitors (varoglutamstat) for Alzheimer's disease, overlapping Virobay's cathepsin-targeted oral small-molecule approach.

TypeEmerging player
Description

Clinical-stage biotech developing emricasan (a pan-caspase inhibitor) for liver fibrosis, conceptually similar to Virobay's small-molecule protease inhibitor approach in hepatic disease.

TypeEmerging player
Description

Specialty pharma historically focused on liver disease (obeticholic acid for NASH/PBC), directly comparable to Virobay's VBY-376 liver fibrosis program in therapeutic area.

TypeDirect peer
Description

Swedish clinical-stage biotech that has historically developed cathepsin S inhibitors and protease-targeted small molecules, making it the closest mechanistic and therapeutic-area peer to Virobay's platform.

TypeEmerging player
Description

Pre-acquisition, Anacor was a boron-based small-molecule biotech with a virtual-like operating model and partnership-driven development; comparable as a small-molecule platform story ultimately validated via M&A.

9Vermillion
TypeEmerging player
Description

Small-cap clinical-stage company developing novel therapeutics with a partnership-driven model; comparable in size, stage, and dependence on partners for late-stage development.

TypeEmerging player
Description

Small clinical-stage biotech with proprietary small-molecule therapeutics in immunology and inflammation; comparable in therapeutic focus and small-cap virtual operating profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Virobay

Small Molecule Pharmaceuticalsvirobayinc.com

Virobay is a privately held, virtual biotechnology company developing small-molecule cathepsin protease inhibitors for autoimmune diseases, neuropathic pain, liver fibrosis, and cancer, advancing six drug candidates through preclinical and Phase 1 stages and partnering with pharmaceutical companies for late-stage development and commercialization.

What Virobay does

Virobay Inc. is a privately held, virtual biotechnology company founded in 2006 in Menlo Park, California, developing small-molecule cathepsin protease inhibitors for autoimmune diseases, neuropathic pain, liver fibrosis, atherosclerosis, and cancer. The company's pipeline comprises six drug candidates — VBY-036, VBY-129, VBY-285, and VBY-891 (cathepsin S inhibitors for pain, autoimmunity, Alzheimer's, and dermatology), VBY-376 (cathepsin B inhibitor for liver fibrosis), and VBY-825 (pan-cathepsin inhibitor for oncology) — characterized as potent, orally bioavailable, reversible inhibitors with picomolar-to-nanomolar potency and selectivity profiles designed to overcome historical cathepsin inhibitor design challenges. Virobay operates an asset-light model with a 1–10 person in-house team that coordinates globally distributed contract research and manufacturing organizations, with senior leaders drawn from Roche, Celera Genomics, Sugen, Merck, and other tier-one organizations.

The company is backed by venture investors including Alta Partners, Sutter Hill Ventures, TPG Growth, Perceptive Advisors, and strategic investor AbbVie, with cumulative disclosed funding on the order of $23M–$24M across a 2006 seed, 2010 Series B ($10M), and 2014 Series B extension ($8M). Virobay is pre-revenue and monetizes exclusively through pharmaceutical partnerships: the model is to advance compounds through preclinical and Phase 1 development, then license or co-develop with larger pharma for late-stage trials and commercialization. The flagship deal is a multi-million dollar January 2012 collaboration with LEO Pharma A/S for VBY-891 in oral psoriasis treatment, which advanced to Phase 1 in 2013 alongside Virobay's wholly owned VBY-036 in neuropathic pain. With no commercialized products, the company has not disclosed revenue, and recent verifiable company-driven updates stop at 2013.

Virobay firmographics

Firmographics
Name
Virobay
Legal name
Virobay Inc.
Website
https://virobayinc.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Virobay is a privately held, virtual biotechnology company developing small-molecule cathepsin protease inhibitors for autoimmune diseases, neuropathic pain, liver fibrosis, and cancer, advancing six drug candidates through preclinical and Phase 1 stages and partnering with pharmaceutical companies for late-stage development and commercialization.
Ownership category
akta.pro rank

Virobay industry classification

Industry
Product category
Small Molecule Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Small molecule drug discovery
  • Cathepsin protease inhibitors
  • Autoimmune disease therapeutics
  • Neuropathic pain treatments
  • Oncology drug development

Where Virobay is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Virobay business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Others

Revenue model

  1. Partnership/Licensing Revenue: Virobay develops drug candidates through clinical development and out-licenses or partners with pharmaceutical companies for later-stage development and commercialization. Revenue would come from upfront payments, milestone payments, and royalties from partnership agreements such as the LEO Pharma collaboration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Virobay product offering

Product offering

Core offering

Virobay discovers and develops orally bioavailable small-molecule cysteine protease (cathepsin) inhibitors as drug candidates for autoimmune diseases, neuropathic pain, liver fibrosis, atherosclerosis, and cancer. The company advances these candidates through preclinical and early clinical stages using a virtual operating model and then partners or licenses them to pharmaceutical companies for late-stage development and commercialization.

Product overview

Virobay is a drug discovery and development company specializing in protease inhibitor design for the treatment of autoimmune diseases, neuropathic pain, liver diseases, and cancer. The company's product portfolio consists of six distinct drug candidates targeting cathepsin proteases: VBY-036 (cathepsin S inhibitor for neuropathic pain/Alzheimer's), VBY-129 (cathepsin S inhibitor for autoimmune diseases), VBY-285 (next-gen cathepsin S inhibitor), VBY-891 (cathepsin S inhibitor for dermatology partnered with LEO Pharma), VBY-376 (cathepsin B inhibitor for liver fibrosis), and VBY-825 (pan-cathepsin inhibitor for oncology). Compounds include both highly selective inhibitors targeting individual cathepsins and broadly acting pan-cathepsin inhibitors. The company operates a virtual model combining in-house expertise with contract research and manufacturing facilities worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • VBY-036 VBY-036 is a next-generation, orally bioavailable, potent, competitive and reversible cathepsin S inhibitor with picomolar enzyme potency and nanomolar cellular potency. It is highly selective against cathepsins B, F, L, and K and is suitable for once-daily dosing in humans. It targets neuropathic pain and Alzheimer's Disease.
  • VBY-129 VBY-129 is a potent, competitive, reversible inhibitor of purified cathepsin S with high selectivity against other human cathepsins. It demonstrated sustained inhibition of cathepsin S after once-daily oral dosing in a Phase 1 clinical trial and targets autoimmune diseases.
  • VBY-285 VBY-285 is a next-generation cathepsin S inhibitor, structurally distinct from VBY-129, VBY-891, and VBY-036. It is a potent, competitive, reversible inhibitor with picomolar potency against cathepsin S, selectively inhibits cathepsin S over B, F, L, and K, and is orally bioavailable in preclinical studies. It has shown efficacy in autoimmunity and neuropathic pain models.
  • VBY-891 VBY-891 is a next-generation cathepsin S inhibitor, structurally distinct from other cathepsin S inhibitors, with picomolar enzyme potency and nanomolar cellular potency, high selectivity against cathepsins L, B, F, and K, and oral bioavailability suitable for once-daily dosing. It is being developed in partnership with LEO Pharma as an oral treatment for psoriasis (dermatology).
  • VBY-376 VBY-376 is a potent, competitive, reversible inhibitor of cathepsin B with nanomolar potency, selectively inhibiting cathepsin B over F, L, V, and S. A human Phase 1 study showed exposure levels overlapping those required for antifibrotic efficacy. It targets liver fibrosis.
  • VBY-825 VBY-825 is a potent, competitive, reversible pan-cathepsin protease inhibitor with picomolar or low nanomolar potency across all cathepsins implicated in cancer. It demonstrated efficacy in spontaneous tumor models with effects on primary tumor burden and tumor vasculature. It targets bone cancer/oncology.

Quantifiable outcome

  • Cathepsin S inhibitor reduced atherosclerotic plaques by 68% in female mice and 36% in male mice after 8 weeks of dosing
  • +3 more outcomes

Companies that use Virobay

Customer profile

Segments5 records

Ideal customer profiles1 record

Virobay technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Virobay partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LEO Pharma A/SflagshipStrategic or Co-development Partner · 1 January 2012Virobay Inc. and LEO Pharma initiated a collaboration in January 2012 to develop an oral treatment for psoriasis using VBY-891, a cathepsin S inhibitor. This multi-million dollar collaboration represents Virobay's primary partnership for dermatology indications. Virobay retains rights to compounds while LEO Pharma provides development and commercialization expertise for the psoriasis indication.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Virobay competitors and assessment

Company assessment

Broad incumbents

  • Galapagos NV: Belgian biotech with a small-molecule pipeline in inflammation and immunology; comparable in therapeutic focus (autoimmune/inflammation) and chemistry modality (oral small molecules) though at a much larger scale.
  • ChemoCentryx (Amgen): Small-molecule immunology company acquired by Amgen, focused on complement and chemokine pathways for autoimmune diseases; comparable as a small-molecule immunology developer targeting similar autoimmune indications.

Emerging players

  • Aldeyra Therapeutics: Clinical-stage biotech developing novel small-molecule therapies for immune-mediated diseases; comparable as a small-cap small-molecule immunology developer pursuing partnerships for commercialization.
  • Conatus Pharmaceuticals: Clinical-stage biotech developing emricasan (a pan-caspase inhibitor) for liver fibrosis, conceptually similar to Virobay's small-molecule protease inhibitor approach in hepatic disease.
  • Intercept Pharmaceuticals: Specialty pharma historically focused on liver disease (obeticholic acid for NASH/PBC), directly comparable to Virobay's VBY-376 liver fibrosis program in therapeutic area.
  • Anacor Pharmaceuticals (Pfizer): Pre-acquisition, Anacor was a boron-based small-molecule biotech with a virtual-like operating model and partnership-driven development; comparable as a small-molecule platform story ultimately validated via M&A.
  • Vermillion: Small-cap clinical-stage company developing novel therapeutics with a partnership-driven model; comparable in size, stage, and dependence on partners for late-stage development.
  • Pharmos Corp: Small clinical-stage biotech with proprietary small-molecule therapeutics in immunology and inflammation; comparable in therapeutic focus and small-cap virtual operating profile.

Direct peers

  • Vivoryon Therapeutics: Germany-based company developing small-molecule cathepsin D inhibitors (varoglutamstat) for Alzheimer's disease, overlapping Virobay's cathepsin-targeted oral small-molecule approach.
  • Medivir AB: Swedish clinical-stage biotech that has historically developed cathepsin S inhibitors and protease-targeted small molecules, making it the closest mechanistic and therapeutic-area peer to Virobay's platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Virobay social profiles

Digital presence

Virobay financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Virobay leadership team

Management profile

Number of profiles

Profiles7 records

Virobay funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Virobay M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virobay

What does Virobay do?

Virobay discovers and develops orally bioavailable small-molecule cysteine protease (cathepsin) inhibitors as drug candidates for autoimmune diseases, neuropathic pain, liver fibrosis, atherosclerosis, and cancer. The company advances these candidates through preclinical and early clinical stages using a virtual operating model and then partners or licenses them to pharmaceutical companies for late-stage development and commercialization.

Is Virobay a public or private company?

Virobay is a private company. It is classified as venture growth investor backed and is currently operating.

When was Virobay founded?

Virobay was founded in 2006. It employs 1 to 10 people.

Where is Virobay based?

Virobay is headquartered in Menlo Park, United States, in the North America region.

How does Virobay make money?

One revenue line is on record: partnership/Licensing Revenue.

Who are Virobay's main competitors?

Broad incumbents on record are Galapagos NV and ChemoCentryx (Amgen). Emerging players are Aldeyra Therapeutics, Conatus Pharmaceuticals, Intercept Pharmaceuticals, Anacor Pharmaceuticals (Pfizer), Vermillion and Pharmos Corp. Direct peers are Vivoryon Therapeutics and Medivir AB.

Does Virobay have an API?

No public API is recorded for Virobay.

What industry is Virobay in?

Virobay's product category is Small Molecule Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals